Zynex (OTCMKTS:ZYXI) had its target price lifted by B. Riley from $10.75 to $12.00 in a research report sent to investors on Tuesday morning, BenzingaRatingsTable reports. B. Riley currently has a buy rating on the stock.
Several other equities research analysts have also issued reports on ZYXI. HC Wainwright started coverage on Zynex in a research report on Monday, September 23rd. They set a buy rating and a $12.00 target price for the company. Zacks Investment Research raised Zynex from a sell rating to a hold rating in a research report on Thursday, June 27th.
Shares of Zynex stock opened at $9.41 on Tuesday. Zynex has a 1 year low of $2.58 and a 1 year high of $13.10. The firm has a market cap of $341.13 million, a PE ratio of 42.77 and a beta of 1.05. The stock has a fifty day moving average price of $10.24 and a 200-day moving average price of $8.49.
In other news, CEO Thomas Sandgaard sold 104,450 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $12.38, for a total transaction of $1,293,091.00. Insiders have sold a total of 304,450 shares of company stock valued at $3,470,270 in the last quarter.
Several hedge funds have recently bought and sold shares of ZYXI. Vanguard Group Inc. bought a new position in shares of Zynex during the 2nd quarter worth $8,257,000. BlackRock Inc. bought a new position in shares of Zynex during the 2nd quarter worth $6,957,000. Calamos Advisors LLC bought a new position in shares of Zynex during the 3rd quarter worth $2,586,000. Northern Trust Corp bought a new position in shares of Zynex during the 2nd quarter worth $627,000. Finally, Acadian Asset Management LLC grew its stake in shares of Zynex by 127.6% during the 2nd quarter. Acadian Asset Management LLC now owns 108,737 shares of the company’s stock worth $978,000 after acquiring an additional 60,960 shares during the period. Institutional investors own 0.05% of the company’s stock.
Zynex Company Profile
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
See Also: What is a conference call?
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.